Understanding the proper tesamorelin dosage is essential for researchers working with the only FDA-approved growth hormone releasing hormone (GHRH) peptide in existence. Tesamorelin (brand name Egrifta) was approved by the FDA in 2010 for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy — making it the most clinically validated GHRH analog available. A pooled analysis of 806 participants across two Phase III randomized controlled trials (Falutz et al.) demonstrated that the standard tesamorelin dosage reduced visceral adipose tissue by approximately 15.4% versus placebo at 26 weeks (p<0.001). The new F8 formulation, EGRIFTA WR, gained FDA approval on March 25, 2025.

PSPeptides carries research-grade tesamorelin from $59.99 at 99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. This guide covers the tesamorelin dosage used in clinical trials, the GHRH mechanism, visceral fat research data, how tesamorelin compares to other GHRH analogs (Sermorelin, CJC-1295), and practical protocol guidance.

For researchers requiring a comprehensive overview of GHRH peptide pharmacology and how the tesamorelin dosage protocol fits into the broader landscape of growth hormone secretagogue research, the sections below provide mechanistic, clinical, and practical guidance designed to support rigorous laboratory investigation.

How Tesamorelin Works: The GHRH Mechanism

Tesamorelin is a synthetic analog of human growth hormone releasing hormone (GHRH 1-44) with a trans-3-hexenoic acid modification that improves stability and bioavailability. The standard tesamorelin dosage activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells through the Gs/cAMP/PKA signaling pathway — stimulating pulsatile growth hormone (GH) release. This is the same receptor pathway that Sermorelin and CJC-1295 target, but tesamorelin is the only GHRH analog with FDA approval and Phase III clinical trial validation.

The GH released in response to the tesamorelin dosage drives IGF-1 elevation, which mediates the compound’s effects on body composition — particularly the reduction of visceral adipose tissue (VAT) that accumulates around internal organs. This visceral fat specificity distinguishes tesamorelin from general weight loss compounds: the tesamorelin dosage targets the metabolically dangerous deep abdominal fat rather than subcutaneous fat. The CJC-1295/Ipamorelin guide covers the GHRH pathway in detail.

Tesamorelin Dosage: The Clinical Protocol

The standard tesamorelin dosage of 2mg daily was established through the Phase III program and is the FDA-approved therapeutic dose. The free reconstitution calculator supports tesamorelin dosage preparation at any concentration. The reconstitution guide covers preparation technique.

Tesamorelin Dosage vs Other GHRH Analogs

The tesamorelin dosage advantage over other GHRH analogs: FDA approval provides the most comprehensive safety and efficacy characterization available for any GHRH peptide. The Phase III validation with 806 participants gives researchers the highest-confidence dosing data in the GHRH class. The stacking guide covers GHRH + GHRP combinations. The half-life chart covers GH peptide timing.

Tesamorelin Dosage: Visceral Fat Research in Detail

The clinical significance of the tesamorelin dosage for visceral fat research cannot be overstated. Visceral adipose tissue (VAT) is the metabolically active deep abdominal fat associated with cardiovascular disease risk, insulin resistance, systemic inflammation, and metabolic syndrome. The pooled Phase III data demonstrating 15.4% VAT reduction with the standard tesamorelin dosage represents one of the strongest evidence bases for any peptide compound targeting metabolic body composition.

Published research also documents that the tesamorelin dosage reduces trunk fat, improves lipid profiles (triglycerides, cholesterol ratios), and may improve cardiovascular biomarkers — effects that extend beyond simple fat reduction to broader metabolic improvement. For researchers studying the GH-visceral fat axis, the tesamorelin dosage protocol provides the most clinically validated starting point available.

Published Research: Key Clinical Studies on Tesamorelin

The evidence base supporting the tesamorelin dosage protocol is unusually robust for a research peptide compound. Three landmark studies establish the clinical foundation that researchers reference when evaluating the standard 2mg daily protocol, and their findings consistently validate the efficacy and tolerability of the compound across diverse study populations.

Falutz et al. (2007 and 2010 — NEJM and JCEM): Two Phase III randomized controlled trials enrolled 806 HIV-positive participants with lipodystrophy-associated visceral adiposity. Subjects receiving the active compound subcutaneously once daily demonstrated a mean 15.4% reduction in visceral adipose tissue (VAT) versus placebo over 26 weeks (p<0.001). Secondary endpoints showed significant reductions in trunk fat mass, triglycerides, and trunk-to-limb fat ratios. GH and IGF-1 levels increased significantly within the normal physiological range, confirming pulsatile GH secretion without supraphysiologic elevation. These trials provided the efficacy data that supported FDA approval in 2010 and remain the primary clinical reference for tesamorelin dosage researchers.

Falutz et al. (2010 — Extension Study): A 26-week open-label extension enrolled subjects who completed the primary Phase III trials. Subjects continuing treatment maintained their visceral fat reductions, while subjects switched from placebo to active treatment showed approximately 11.2% VAT reduction during weeks 26–52. Researchers noted that GH axis effects normalized quickly after discontinuation, supporting the reversibility of the mechanism and its suitability for cycle-based research protocols investigating GH-axis recovery dynamics.

Stanley et al. (2012 — JCEM): A separate Phase II trial examined the protocol in non-HIV adults with abdominal obesity. Forty subjects received 2mg tesamorelin daily for 13 weeks. Research data showed significant VAT reductions compared to placebo (approximately 12.8%), along with improvements in visceral-to-subcutaneous fat ratios and triglyceride levels. Lean mass was preserved, and subcutaneous fat was not significantly affected — confirming the visceral-fat specificity of the mechanism through the GH/IGF-1 signaling axis.

Taken together, these study populations demonstrate that this GHRH protocol produces consistent, reproducible visceral fat effects across diverse research populations. The PubMed research archive on tesamorelin indexes over 40 peer-reviewed publications examining the mechanism, safety profile, and metabolic effects relevant to ongoing research in 2026.

Safety Profile and Adverse Event Data

Researchers studying this GHRH peptide should be familiar with the adverse event profile documented in Phase III clinical trials. The safety data from the 806-participant pooled analysis provides the most comprehensive reference available for any GHRH analog currently under active investigation worldwide.

Injection site reactions were the most commonly reported adverse events, occurring in approximately 24.5% of subjects receiving the active compound versus 13.3% in placebo. These reactions were predominantly mild to moderate in severity and included erythema, pruritus, pain, and urticaria localized to the injection site. Rotating administration sites across the periumbilical region reduced reaction incidence in longer-duration studies, a finding that is now incorporated into standard research protocol design for this compound.

Fluid retention effects including peripheral edema, arthralgia, myalgia, and carpal tunnel syndrome occurred in approximately 6–10% of subjects. These effects are consistent with GH-related fluid retention and were generally transient in nature. The Phase III program recorded approximately 5.3% arthralgia in the active group versus 4.7% in placebo. Researchers noted that these effects did not lead to significant discontinuation rates across the trial populations.

Glucose and IGF-1 parameters: The 2mg tesamorelin dosage raised IGF-1 levels above the upper limit of normal in approximately 36% of subjects at some point during the 26-week trials. Fasting glucose and HbA1c were monitored throughout the studies; Phase III data showed no statistically significant worsening of glucose tolerance versus placebo at the primary endpoint — a key differentiator from direct synthetic GH administration that researchers frequently cite in comparative analyses of GH axis interventions.

Immunogenicity data: Approximately 49% of subjects developed anti-tesamorelin antibodies by Week 26, but antibody development did not substantially attenuate efficacy — VAT reductions were maintained in antibody-positive subjects at comparable magnitudes to antibody-negative subjects. Cross-reactivity with endogenous GHRH was not observed in the clinical trial populations, supporting the compound’s receptor selectivity and favorable long-term tolerability profile.

Researchers should also note that the Phase III trials documented a low rate of study discontinuation attributable to adverse events — approximately 3.8% in the active treatment group versus 2.9% in placebo, a difference that was not statistically significant. This overall tolerability profile supports the use of this GHRH analog as a long-term research compound in appropriately designed studies, and the accumulated post-approval pharmacovigilance data since 2010 continues to align with the Phase III safety findings.

Reconstitution and Storage Protocol

Proper handling is critical for maintaining research integrity and compound stability. The reconstitution and storage requirements for this peptide follow specific conditions that differ in some respects from other lyophilized GHRH compounds available for research use, and adherence to these protocols directly impacts experimental reproducibility.

Lyophilized storage: Tesamorelin in lyophilized powder form should be stored at 2–8°C and protected from light. The peptide storage guide provides detailed temperature and light exposure recommendations for preserving compound integrity through the full shelf life. Short-term exposure to room temperature during handling is acceptable but thermal cycling should be minimized to maintain structural and biological stability of the GHRH analog.

Reconstitution procedure: The tesamorelin dosage protocol supports reconstitution in either sterile water for injection (SWFI) or bacteriostatic water with 0.9% benzyl alcohol. SWFI-reconstituted solutions should be used within 24 hours, while bacteriostatic water preparations remain stable for up to 21 days at 2–8°C. To prepare a standard 2mg/mL working solution, add 1.0mL of bacteriostatic water to one 2mg vial of lyophilized peptide, directing the liquid stream along the inner vial wall to avoid foam formation. The step-by-step reconstitution guide provides visual syringe diagrams that support accurate preparation at any research facility.

Administration technique: The clinical protocol specifies subcutaneous injection in the periumbilical abdominal region. Injection sites should be rotated within this region to minimize cumulative local tissue reactions — a practice that demonstrably reduced reaction incidence in Phase III extension studies. Insulin syringes (28–31 gauge, 0.5″ needle) are appropriate for subcutaneous delivery at standard volumes. Researchers can reference the peptide half-life reference chart to plan optimal daily timing of the tesamorelin dosage relative to circadian GH secretion patterns and feeding cycles.

Choosing the Right GHRH Peptide for Your Research

For researchers evaluating GHRH analogs in 2026, the tesamorelin dosage protocol offers the highest level of clinical validation currently available. However, the selection between this compound, sermorelin, and CJC-1295 ultimately depends on specific research endpoints, required evidence thresholds, and the biological mechanisms under investigation.

The tesamorelin dosage approach is the definitive choice when visceral adipose tissue metabolism, FDA-validated dosing standards, or GH pulsatility dynamics form the primary research objective. The extensive Phase III evidence base makes this compound the benchmark reference for GH-visceral fat axis investigation. The CJC-1295/Ipamorelin research guide provides a substantive comparison for investigators weighing GHRH combination protocols against the pure GHRH agonist mechanism.

For research programs addressing broader GH secretagogue applications — including tissue recovery, sleep architecture, or combined GH pulse amplification — other GHRH peptides or GHRH/GHRP combinations may offer distinct mechanistic advantages. Resources including the peptides for muscle growth and recovery research guide and the best peptides for weight loss research overview provide context for selecting the most appropriate GH secretagogue protocol for specific investigative goals.

Researchers who have established their GH secretagogue research framework may also benefit from reviewing the peptide cycling guide, which addresses the pharmacodynamic rationale for on-off protocols in GH-axis research — a consideration particularly relevant to GHRH analog studies given the extension study data showing rapid GH axis normalization after discontinuation of treatment. Understanding the full lifecycle of the research protocol, from initial tesamorelin dosage preparation through to washout periods, is essential for designing studies that can generate reliable, reproducible data on visceral fat metabolism and GH pulsatility in research model populations.

Buy Tesamorelin at PSPeptides

PSPeptides carries research-grade tesamorelin from $59.99. 99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. Free shipping, same-day processing including Sundays, zero fees on Affirm, Afterpay, Zelle, cards, Apple Pay, Google Pay. bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads in the same checkout. free reconstitution calculator for tesamorelin dosage preparation. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670. Discrete plain white mailer packaging with generic billing descriptors. The tesamorelin dosage protocol — and the entire GH secretagogue catalog (Sermorelin, CJC-1295, CJC/Ipa Blend, Ipamorelin) — is available at PSPeptides. PubMed indexes tesamorelin clinical data. Wikipedia covers tesamorelin pharmacology. The weight loss peptide guide covers the metabolic landscape. The muscle growth guide covers GH-mediated body composition research.

PSPeptides: Quality, Supplies, and 24/7 Support

99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. US manufacturing. Same-day processing seven days a week including Sundays. Free shipping on every domestic order. Free international shipping to 30+ countries over $150. Zero fees on all payment methods. Complete supplies — bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads — in one checkout. free reconstitution calculator with visual syringe diagrams. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670. Discrete plain white mailer packaging with generic billing descriptors. 5-star rating from thousands of verified customers at pspeptides.com/shop.

Understanding tesamorelin dosage is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is the standard tesamorelin dosage?

2mg subcutaneous daily — the FDA-approved dose validated in Phase III trials with 806 participants showing 15.4% visceral fat reduction vs placebo. This tesamorelin dosage was established through the Falutz et al. program and represents the only clinically validated GHRH peptide protocol with FDA approval status. Research subjects in the 26-week trials maintained consistent VAT reductions throughout the study period without dose escalation requirements.

Is tesamorelin FDA-approved?

Yes — tesamorelin (Egrifta) was FDA-approved in 2010 for HIV-associated lipodystrophy. The updated EGRIFTA WR formulation gained approval on March 25, 2025. It is the only FDA-approved GHRH peptide, making the associated protocol the most clinically validated option for GH-axis research available to investigators today. No other GHRH synthetic analog has achieved comparable regulatory milestones.

Does PSPeptides sell tesamorelin?

Yes. PSPeptides offers research-grade tesamorelin from $59.99 with 99%+ HPLC-verified purity, batch-specific COAs from independent laboratories, free shipping, and same-day processing. The tesamorelin dosage preparation is supported by a free reconstitution calculator and 24/7 technical support via chat, email, and phone.

How does tesamorelin compare to Sermorelin?

Tesamorelin has FDA approval and Phase III validation with 806 participants, while Sermorelin’s original approval was withdrawn in the early 2000s. Both compounds target the GHRHR receptor to stimulate pulsatile GH release, but tesamorelin has a superior clinical evidence base and greater receptor binding affinity due to its trans-3-hexenoic acid modification. PSPeptides carries both compounds for researchers conducting comparative GHRH receptor pharmacology studies.

What is the reconstitution protocol for tesamorelin research?

The standard approach uses bacteriostatic water or sterile water for injection. For a 2mg/mL concentration, add 1.0mL of bacteriostatic water to 2mg lyophilized tesamorelin. Reconstituted solutions should be stored at 2–8°C and used within 24 hours when prepared with SWFI, or up to 21 days when using bacteriostatic water with benzyl alcohol preservative. The complete tesamorelin dosage preparation workflow — including syringe sizing, injection technique, and site rotation — is detailed in the PSPeptides reconstitution guide.

All PSPeptides products are sold exclusively for research and laboratory use.